Artiva Biotherapeutics, Inc.'s Lock-Up Period To End on January 15th (NASDAQ:ARTV)

Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) lock-up period will expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

ARTV has been the subject of a number of recent analyst reports. HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a "buy" rating and a $20.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $21.00.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV traded down $0.32 during mid-day trading on Wednesday, reaching $10.26. The company's stock had a trading volume of 62,378 shares, compared to its average volume of 51,096. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31. The business's fifty day simple moving average is $11.36.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Sell-side analysts anticipate that Artiva Biotherapeutics will post -4.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in ARTV. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the third quarter worth about $42,000. MetLife Investment Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $135,000. JPMorgan Chase & Co. purchased a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $166,000. Barclays PLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $304,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Artiva Biotherapeutics in the third quarter worth $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.